Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Apr 1, 2011

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Roche Diagnostics has appointed Robert Yates to be the new Head of Roche Applied Science, a position he will take over from Manfred Baier, who will be retiring from the company at the end of the year. Yates formerly was global head of business development and licensing at Roche Diagnostics.


The National Human Genome Research Institute has named Laura Lyman Rodriguez to head its Office of Policy, Communications, and Education, NHGRI said this week. Rodriguez will oversee development of the institute's policy positions on the ethical, legal and social implications of human genome research. She also is responsible for communicating information about programs at the institute, tracking and analyzing legislation, and developing education and outreach programs. She joined NHGRI in 2002 after serving as a study director at the Institute of Medicine.


Rosetta Genomics said this week that President and CEO Kenneth Berlin will leave his position on the company's board of directors. The move is an effort to remain in standing with the company's corporate governance and division of responsibility between the board and the president and CEO. The board has elected current Board Observer Brian Markison, former chairman and CEO of King Pharmaceuticals, to be fill the empty seat.


GenMark Diagnostics said this week that senior vice president of product development and manufacturing Pankaj Singhal will leave the company, effective April 29, and that he will be replaced by diagnostics industry executive Sue Pierce, according to a filing with the US Securities and Exchange Commission. Pierce spent 11 years at Ventana Medical Systems, part of the Roche Group, and 14 years at Abbott Laboratories' Diagnostics Division.


The American College of Medical Genetics has appointed Wayne Grody to be the organization's new president, a title he will take over from Bruce Korf. Grody is a professor in the departments of pathology and laboratory medicine, pediatrics, and human genetics at the University of California, Los Angeles School of Medicine. He also is director of the Diagnostic Molecular Pathology Laboratory at the UCLA Medical Center. Korf is departing after completing his two-year term as ACMG president.


Brook Byers plans to retire from his position on Genomic Health's board of directors, of which he has been a member since 2001, at the company's upcoming stockholder's meeting in June.


Nanosphere said this week that James Nahirny will not stand for re-election to the company's board of directors. Nahirny is a managing director of Bain Capital Ventures and has been a member of Nanosphere's board since 2006. The company said it does not plan to replace Nahimy, and will reduce the size of its board from eight to seven members.


RainDance Technologies has appointed Laura Deming to be senior vice president of product development and named Joseph Malandrakis to be senior product development counsel.

Deming has spent 25 years in development in the genomics, proteomics, and in vitro diagnostics areas, including serving as VP of R&D and operations at WaveRx, and working in development at Cytyc, PerSeptive Biosystems, and Millipore.
Malandrakis worked for nearly 30 years at Applied Biosystems/Applera, where he was VP of global services and solutions and a VP in sales.


Genelux announced the resignation of Jodi Devlin. She resigned on March 10 after two months as president of the firm.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.